Guardant Health (NASDAQ:GH) CFO Michael Brian Bell Sells 2,000 Shares of Stock

Guardant Health, Inc. (NASDAQ:GH) CFO Michael Brian Bell sold 2,000 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $128.62, for a total value of $257,240.00. Following the transaction, the chief financial officer directly owned 47,509 shares of the company’s stock, valued at approximately $6,110,607.58. This represents a 4.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Michael Brian Bell also recently made the following trade(s):

• On Monday, March 16th, Michael Brian Bell sold 3,000 shares of Guardant Health stock. The stock was sold at an average price of $87.04, for a total value of $261,120.00.

Guardant Health Stock Performance

NASDAQ:GH opened at $124.89 on Tuesday. The stock has a 50-day simple moving average of $100.13 and a 200-day simple moving average of $101.32. The stock has a market cap of $16.56 billion, a P/E ratio of -36.84 and a beta of 1.61. Guardant Health, Inc. has a 1 year low of $40.35 and a 1 year high of $134.28.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Stifel Nicolaus upped their price objective on Guardant Health from $120.00 to $130.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. Leerink Partners upped their target price on Guardant Health from $170.00 to $180.00 and gave the company an “outperform” rating in a research report on Friday, February 20th. TD Cowen reissued a “buy” rating on shares of Guardant Health in a research report on Thursday, May 21st. Canaccord Genuity Group raised their price target on Guardant Health from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday, February 20th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a research note on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $139.80.

Institutional Trading of Guardant Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in Guardant Health by 2.1% during the 4th quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company’s stock valued at $1,242,101,000 after acquiring an additional 251,939 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Guardant Health by 33.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock valued at $575,670,000 after acquiring an additional 1,414,441 shares during the last quarter. Franklin Resources Inc. raised its stake in Guardant Health by 14.9% during the 4th quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company’s stock valued at $343,348,000 after acquiring an additional 435,232 shares during the last quarter. Geode Capital Management LLC raised its stake in Guardant Health by 9.4% during the 4th quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock valued at $328,297,000 after acquiring an additional 277,001 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. raised its stake in Guardant Health by 3.0% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 2,441,730 shares of the company’s stock valued at $249,398,000 after acquiring an additional 72,162 shares during the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.